These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 16946346)

  • 21. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders.
    Bradstreet JJ; Smith S; Granpeesheh D; El-Dahr JM; Rossignol D
    Med Hypotheses; 2007; 68(5):979-87. PubMed ID: 17150311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental studies on the endocrine side effects of new aldosterone antagonists.
    Nishino Y; Schröder H; el Etreby MF
    Arzneimittelforschung; 1988 Dec; 38(12):1800-5. PubMed ID: 3245852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy.
    Epstein M
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):310-1. PubMed ID: 16932450
    [No Abstract]   [Full Text] [Related]  

  • 24. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Controlled clinical trial for the comparison of tolerance of two aldosterone antagonists].
    Leizorovicz A; Guenaneche F; Luciani J; Boissel JP
    Therapie; 1991; 46(4):327-31. PubMed ID: 1948810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What's old is new again. Spironolactone and heart failure.
    Lock M; Chun R
    Can Fam Physician; 1999 Nov; 45():2621-2. PubMed ID: 10587769
    [No Abstract]   [Full Text] [Related]  

  • 27. Everything old is new again: spironolactone and metformin in the treatment of acne.
    Bergstrom KG
    J Drugs Dermatol; 2010 May; 9(5):569-71. PubMed ID: 20480804
    [No Abstract]   [Full Text] [Related]  

  • 28. [No effect of spironolactone on bulimia nervosa symptoms].
    von Wietersheim J; Müller-Bock V; Rauh S; Danner B; Chrenko K; Bühler G
    Psychother Psychosom Med Psychol; 2008 Dec; 58(12):470-4. PubMed ID: 18666040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spironolactone use and renal toxicity: population based longitudinal analysis.
    Wei L; Struthers AD; Fahey T; Watson AD; Macdonald TM
    BMJ; 2010 May; 340():c1768. PubMed ID: 20483947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
    Abbas Z; Mumtaz K; Salam A; Jafri W
    J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spironolactone induced agranulocytosis.
    Ferguson I; Fogg C; Baughan P
    Med J Aust; 1993 Dec 6-20; 159(11-12):837. PubMed ID: 8264493
    [No Abstract]   [Full Text] [Related]  

  • 36. Spironolactone and risk of upper gastrointestinal events: spironolactone may not be guilty.
    Campbell E; Shonde A; Foley S
    BMJ; 2006 Sep; 333(7566):500; author reply 500-1. PubMed ID: 16946346
    [No Abstract]   [Full Text] [Related]  

  • 37. Spironolactone and risk of upper gastrointestinal events: causality remains unconvincing.
    Jones GP
    BMJ; 2006 Sep; 333(7566):501. PubMed ID: 16946351
    [No Abstract]   [Full Text] [Related]  

  • 38. Spironolactone and risk of upper gastrointestinal events: association is unproved.
    Dawwas MF
    BMJ; 2006 Sep; 333(7566):501. PubMed ID: 16946352
    [No Abstract]   [Full Text] [Related]  

  • 39. Upper gastrointestinal bleeding and spironolactone.
    Prescrire Int; 2011 Apr; 20(115):98-9. PubMed ID: 21648213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of spironolactone in dermatology.
    Rathnayake D; Sinclair R
    Skinmed; 2010; 8(6):328-32; quiz 333. PubMed ID: 21413648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.